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Two different types of adipose tissues can be found in humans enabling them to respond to starvation and cold:
white adipose tissue (WAT) is generally known and stores excess energy in the form of triacylglycerol (TG), insulates
against cold, and serves as a mechanical cushion. Brown adipose tissue (BAT) helps newborns to cope with cold.
BAT has the capacity to uncouple the mitochondrial respiratory chain, thereby generating heat rather than
adenosine triphosphate (ATP). The previously widely held view was that BAT disappears rapidly after birth and is no
longer present in adult humans. Using positron emission tomography (PET), however, it was recently shown that
metabolically active BAT occurs in defined regions and scattered in WAT of the adult and possibly has an influence
on whole-body energy homeostasis. In obese individuals adipose tissue is at the center of metabolic syndrome.
Targeting of WAT by thiazolidinediones (TZDs), activators of peroxisome proliferator-activated receptor γ (PPARγ) a
‘master’ regulator of fat cell biology, is a current therapy for the treatment of type 2 diabetes. Since its unique
capacity to increase energy consumption of the body and to dissipate surplus energy as heat, BAT offers new
perspectives as a therapeutic target for the treatment of obesity and associated diseases such as type 2 diabetes
and metabolic syndrome. Recent discoveries of new signaling pathways of BAT development give rise to new
therapeutic possibilities in order to influence BAT content and activity.
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WAT is the largest lipid and energy storage in the
human body. Excessive body fat, however, leads to insu-
lin resistance, dyslipidaemia and type 2 diabetes. Over a
long time it was believed that WAT is hormonally inert,
but this paradigm is now obsolete. Today it is estimated,
that the adipose organ is the largest endocrine organ of
the human body [1]. Adipose tissue mainly produces
and secretes cytokines such as adiponectin (encoded by
the murine gene Adipoq), leptin (encoded by the murine
gene Lep), resistin, tumor necrosis factor α (TNFα) and
interleukins (ILs), which are referred to as adipokines
according to their site of secretion [2]. In healthy (lean)
subjects, adiponectin has a positive insulin sensitizing ef-
fect on other tissues [3]. Leptin is secreted by adipocytes
and suppresses appetite by binding to leptin receptors in
the central nervous system (CNS) [4]. In obesity, how-
ever, different adipokines take over control. Among* Correspondence: bodo.haas@bfarm.de
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reproduction in any medium, provided the orothers, resistin, IL-1, IL-6, and TNFα are secreted from
adipocytes, fibroblasts, macrophages and monocytes
which reside in adipose tissue. These adipokines are
described to be involved in mediating insulin resistance
in peripheral tissues and to increase the risk for type 2
diabetes [5-8]. Excess adiposity is not only associated
with a dysregulation in adipokine profile, but also with
an increased portal release of free fatty acids (FFA). The
high concentrations of FFA decrease the hepatic degrad-
ation of apolipoprotein B and insulin, which may con-
tribute to the dyslipidemia, hyperinsulinemia, and
insulin resistance observed in visceral obesity [9].
A current pharmacological approach to counteract in-
sulin resistance and type 2 diabetes is the use of thiazoli-
dinediones (TZDs), which are agonists on peroxisome
proliferator-activated receptor γ (PPARγ). TZDs pro-
mote differentiation of preadipocytes into white adipo-
cytes [10] and are assumed to redirect FFA away from
skeletal muscle towards adipose tissue (the so-called
lipid steal hypothesis) [11,12]. TZDs are also implicated
in positively influencing insulin resistance by decreasing
the expression of TNFα, IL-1, and resistin whiled. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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back of this therapeutic approach is weight gain caused
by the accumulation of differentiated adipocytes, fluid
retention, and an increased risk of cardiovascular events.
These side effects are probably caused by the classical
agonist action of TZDs. Choi et al. [14] have currently
described a differential regulation of PPARγ. Ligands
which prevent the high-fat diet (TNFα)-induced phos-
phorylation of Ser 273 of PPARγ by CDK5 and only have
minimal agonist activity still retain a potent anti-diabetic
effect [14,15]. Phosphorylation of PPARγ by CDK5 does
not change its transcriptional activity per se but changes
the expression of specific genes (e.g. reduction in Adipoq
expression) (Figure 1).
Promising partial PPARγ agonists such as NS-1 (5Z)-5-
[4-hydroxy-3-methoxy-phenyl) methylene] thiazolidine-2,
4-dione) or balaglitazone are currently investigated
[16,17]. NS-1 induced adipogenesis in vitro to a 25 fold
lesser extent than pioglitazone and improved hypergly-
cemia and insulin resistance in diet-induced obesity mice
without significant weight gain. Balaglitazone already
underwent phase III clinical trials and showed significant
improvement in glucose handling and hemoglobin A1c
(HbA1c) levels comparable to pioglitazone. Importantly,
side effects like fluid retention and fat accumulation were
less pronounced in the balaglitazone groups [18]. Thus,
identification of ‘partial’ PPARγ agonists which preventFigure 1 Regulation of PPARγ activity in conditions of a standard die
insulin-resistant state) in WAT of mice. The activity of PPARγ is differentiall
Obesity and insulin resistance, both a result of a high-fat diet, lead to the produ
activate CDK5, which in turn phosphorylates serine 273 on PPARγ thereby induc
unphosphorylated PPARγ. Differential induction and repression of gene sets are
phosphorylation of PPARγ by CDK5, which may result in the expression of the s
dependent kinase 5; FFA, free fatty acids; PPARγ, peroxisome proliferator-activatephosphorylation of Ser 273 but do not show classical
agonist action might lead to more specific therapies redu-
cing the emergence of side effects [14].
Another class of antidiabetic drugs, the sulfonylureas,
which stimulate insulin secretion by blocking ATP-
dependent potassium channels of pancreatic β-cells,
have also been implicated to act on human white adipo-
cytes. It has been demonstrated that glimeperide and
glibencalmide induce the differentiation of human white
preadipocytes and suppress cytokine expression probably
by activation of PPARγ [19].
Another approach to target adipocytes is to in-
crease lipolysis. Lipolysis in adipocytes is mediated by
norepinephrin (NE) [20]. NE binds to β-adrenoceptors
(β-ARs), which are highly abundant on the surface of
adipocytes, and thereby activates adenylate cyclase (AC)
which increases intracellular cAMP levels. As a conse-
quence hormone-sensitive lipase (HSL) and perilipin are
phosphorylated by PKA leading to the release of FFA.
However, FFA themselves could increase insulin resist-
ance, as mentioned above. This process is tightly regu-
lated by the cGMP-inhibited phosphodiesterase 3B
(PDE3B), which is expressed in white and brown adipo-
cytes. Activation of PDE3B leads to increased hydrolysis
of cAMP and thereby inhibition of catecholamine-
induced lipolysis, reduction in insulin-induced glucose
uptake, and lipogenesis (reviewed in [21]). Using thet (lean, insulin-sensitive state) compared to a high-fat diet (obese,
y regulated during standard diet (left) and high-fat diet (right) conditions.
ction of inflammatory cytokines, such as TNFα. Both FFA and TNFα can
ing the expression of different gene family sets compared to
represented by A, B, and C. Furthermore, some PPARγ ligands block the
ame gene family as under a normal diet. Abbreviations: CDK5, cyclin-
d receptor γ; TNFα, tumor necrosis factor α.
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antilipolytic effect on human adipose tissue in vivo is
mediated by stimulation of PDE3 [22]. Targeted-inhibition
of PDE3B in conjunction with a β-AR agonist could there-
fore be a promising approach to increase intracellular
cAMP levels in adipocytes. However, to date it is not
known whether this approach is feasible due to the release
of FFA. Furthermore, β-AR agonists and PDE inhibitors
could have cardiovascular side effects.
Brown adipose tissue physiology
In contrast to WAT, brown adipose tissue (BAT) com-
busts energy and releases heat. This unique function
allows newborns to maintain body temperature in cold
environments (non-shivering thermogenesis). BAT and
WAT differ not only at the functional but also on the
morphological and molecular levels. White adipocytes
are usually large, round cells with a diameter that varies
from 25–200 micrometer, and contain a large unilocular
lipid droplet surrounded by a thin layer of cytoplasm
with few mitochondria. The nucleus is flattened and
located on the periphery. In contrast, brown adipocytes
are cells with polygonal shape, normal cytoplasm with
multilocular lipid droplets, and the nucleus is located
centrally. Their brown color is due to the large quan-
tity of mitochondria exhibiting numerous cristae.
The main biological function of brown adipocytes is
thermogenesis; energy storage in the form of lipids
takes place but to a lesser extent to that of white adi-
pocytes [23].
In infants, BAT is mainly localized in the neck, supra-
clavicular, in the axillae, and peri-/suprarenal. After birth
BAT content is high accounting for 2–5% of body weight
but gradually decreases during the first years [24,25].
The ability to generate heat (thermogenic capacity)
results from a protein referred to as uncoupling protein
1 (UCP1) [26]. It is found exclusively in brown adipo-
cytes, where it ensures uncoupling of the mitochondrial
respiratory chain. UCP1 forms a pore in the inner mito-
chondrial membrane, leading to the break-down of the
electrochemical proton gradient (proton leak), which is
required for the activation of ATP synthesis in the mito-
chondrial matrix. As a result, ATP synthesis is blunt and
excess energy is released as heat. UCP1 is activated
among others by FFA and thus its activity is directly
coupled to lipolysis. Cold stimuli lead to activation of
the sympathetic nervous system (SNS) and the release of
NE at the sympathetic nerve terminals, which profusely
innervate the BAT. NE binds to β3-ARs, which are
highly abundant on the surface of brown adipocytes, and
activates lipolysis. The subsequent release of FFA acti-
vates UCP1. Additionally, NE increases mitochondrial
biogenesis and the expression of Ucp1 via activation of
p38 mitogen-activated protein kinase (p38MAPK) andPPARγ coactivator 1α (PGC1α) [27]. Thus, prolonged
cold exposure triggers brown adipocytes to produce
more heat. Brown adipocytes can sufficiently provide
themselves with lipids as they express insulin receptors
and glucose transporters and thus are able to take up
larger amounts of glucose, a substrate for lipogenesis.
The insulin pathway is crucial for the regulation of adi-
pogenesis, Ucp1 expression, and mitochondrial biogen-
esis [28]. Insulin can further affect thermogenesis by
increasing substrate uptake by BAT and increasing sym-
pathetic activity mediated by the hypothalamus [29].
These factors may be connected to the thermic effect of
food [30]. In experiments with brown adipocytes derived
from mice it was demonstrated that nitric oxide (NO)
and cyclic guanosine monophosphate (cGMP) can in-
crease Ucp1 expression and mitochondrial biogenesis via
protein kinase G (PKG). Simultaneously, the activated
cGMP pathway increases the differentiation of preadipo-
cytes into mature brown adipocytes by interfering with
the RhoA/ROCK and insulin signaling pathways [31,32].
Also regulation of the cGMP cascade in BAT and WAT
has recently been shown for natriuretic peptides (NPs)
via the NP receptor A (NPRA) and the NP clearance re-
ceptor (NPRC) [33]. In contrast, Becerril et al. [34]
demonstrated, that inducible NO synthase (iNOS)-
knockout mice showed an increased expression of genes
involved in brown adipocyte function (Pgc1a, Ucp1, and
Ucp3) and brown adipogenesis (Prdm16 and Bmp7).
Moreover, deletion of the iNOS gene improves the
brown-like phenotype and the molecular function of
brown fat in Lep-deficient obese (ob/ob) mice, which is
characterized by a “white-like” appearance of BAT. Thus,
further studies are needed to disentangle the role of NO
in the physiology of BAT.
Brown adipocyte function is further regulated by thy-
roid hormones because they express high amounts of
thyroid hormone receptors and the enzyme deiodinase
type 2 (D2, encoded by the murine gene Dio2), which
converts thyroxine (T4) into the more potent triiodo-
thyronine (T3). T3 promotes mitochondrial biogenesis,
induces the expression of Ucp1, and increases the activ-
ity of brown adipocytes [35,36]. Expression and activity
of D2 can be triggered by cAMP. Bile acids can mediate
cAMP-dependent D2 activation via the G-protein-
coupled receptor TGR5 in brown adipocytes leading to
an increase in energy expenditure [37] (Figure 2).
Thermogenesis and BAT activity is under tight con-
trol of the CNS. BAT is innervated by distinct nuclei
of the hypothalamus, which coordinates signals from
temperature changes and food intake [38]. A crucial role
in hypothalamic regulation of sympathetic outflow and
BAT thermogenesis plays AMP-activated protein kinase
(AMPK). The inhibition of AMPK by leptin in the hypo-
thalamus is an important mechanism in the regulation
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phosphatase 1B (PTP1B) has been implicated in interfer-
ing with leptin signaling in the hypothalamus [39]. Using
neuronal Ptb1b knock-out mice, Xue et al. [40] demon-
strated that absence of Ptb1b in the hypothalamus
results in increased leptin signaling and augmented in-
hibition of hypothalamic AMPK. As a consequence
neuronal signaling to BAT is altered leading to increased
AMPK activity in BAT with increased uncoupling and
mitochondrial biogenesis. Inhibition of AMPK by central
administration of T3 to rats leads to reduced body
weight without altering food intake due to increased
SNS activity and upregulation of thermogenic markers
in BAT. Importantly, administration of T3 to a single
nucleus of the hypothalamus could entirely replicate
effects on BAT achieved with peripherally applied T3 inFigure 2 Mechanisms of BAT activation. Schematic overview of the com
stimuli. Abbreviations: AC, adenylate cyclase; AKT1, protein kinase B; BA, bile
guanosine monophosphate, D2, deiodinase type 2; FAS, fatty acid synthase
HSL, hormone-sensitive lipase; IR, insulin receptor; IRS, insulin receptor subs
NPRA, NP repector A; NPRC, NP clearance receptor; p38MAPK, p38 mitogen
phosphoinositide 3 kinase; PKA, protein kinase A; PKCζ, protein kinase C ζ;
ROCK, Rho-associated protein kinase; T4, thyroxine; T3, triiodothyronine; TG
receptor; UCP1, uncoupling protein 1; β3AR, β3-adrenoceptor.higher doses [41]. Currently, bone morphogenic protein
8B (BMP8B) has, besides its effect on brown adipocytes,
also been described to have central effects on BAT.
Bmp8b−/− mice display altered neuropeptide levels and
reduced phosphorylation of hypothalamic AMPK. Cen-
tral BMP8B treatment resulted in increased thermogen-
esis in BAT via neuronal activation of regulatory nuclei
in the hypothalamus [42].
BAT in adult humans
In the last decade it could be demonstrated by using
positron emission tomography (PET) that adult humans
also possess metabolically active BAT [43-46]. Originally,
PET was used in conjunction with computer tomog-
raphy (CT) to image tumors and metastases [47]. Tumor
tissues have a higher metabolic activity and thus takeplex signaling network leading to activation of BAT by exogenous
acids; cAMP, cyclic adenosine monophosphate; cGMP, cyclic
; FFA, free fatty acids; GC, guanylate cyclase; Gs, stimulatory G protein;
trate NE, norepinephrin; NO, nitric oxide; NPs, natriuretic peptides;
-activated protein kinase; PDE, phosphodiesterase; PI3K,
PKGI, protein kinase G 1; RhoA, ras homolog gene family member A;
, triacylglycerol; TGR5, G-protein-coupled receptor; TR, thyroid hormone
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as the Warburg effect. Cancer patients injected with
radioactively labeled glucose (2-deoxy-2[18F]fluoro-D-
glucose, FDG), take up FDG in tumor tissue by sodium-
independent glucose transporters (e.g. GLUT1, GLUT3
and GLUT4). After passing the initial phase of glucose
metabolism and phosphorylation by hexokinase to the
6-phosphate form, FDG does not enter the Krebs cycle
and is trapped in the cell. This results in a strong signal
of tumor tissues in the PETscan. It was noted that in
some PET scans other regions also showed a symmet-
rical, high FDG uptake, especially around the collar
bone (supraclavicular), the mediastinum (para-aortic),
along the spinal column (paravertebral), and in the kid-
neys (supra-/perirenal) [47,48]. After the combination
of PET with CT (PET-CT), it soon became clear that
the unusual pattern is not caused by muscles, but ra-
ther by a tissue with a lower density such as adipose
tissue. White fat depots, however, show only marginal
glucose uptake and hardly give a signal in PET-CT. It
took a rather long time until it was concluded that the
observed signals are BAT [48]. Additionally, subjects
who were exposed to cold prior to PET scans, show an
even stronger FDG uptake in BAT [45,49]. However,
β-AR antagonists such as propranolol (~1 mg/kg) re-
duce FDG uptake [50,51]. Studies of biopsies from the
supraclavicular region in 2009 finally provided clear
proof that the excised tissue is BAT [46,52]. The ex-
pression of specific genes such as UCP1 was shown
first, followed by the histological examination, which
showed the presence of multilocular lipid droplets, an
unequivocal characteristic of BAT.
Lineage development of white and brown adipocytes
Adipocytes derive from multipotent mesenchymal stem
cells (MSCs), which emerge from the mesoderm of the
embryo. White adipocytes differentiate from pericytes,
which derive from the lateral mesoderm [53]. In the
course of development adipoblasts (precursor cells) are
derived from the MSCs which further develop into prea-
dipocytes. Preadipocytes finally are able to differentiate
into mature white adipocytes. A similar course was pro-
posed for the development of brown adipocytes. Surpris-
ingly, it has recently been found that brown adipocytes
carry the genetic signature of a muscle cell. Muscle pre-
cursor cells derive from the paraxial mesoderm and ex-
press the gene Myf5. They can develop into both skeletal
muscle cells and brown adipocytes [54,55]. A driving
factor inducing the differentiation of progenitors (Myf5-
positiv and -negativ) into brown adipocytes via the
activation of transcription factors such as PR domain
containing 16 (PRDM16), CCAAT/enhancer-binding
protein β (C/EBPβ), and PGC1α is the cytokine BMP7,
which belongs to the TGFβ superfamily [56,57]. It hasbeen shown in lineage tracing studies that the interscap-
ular and perirenal BAT depots of mice are derived from
Myf5-positive muscle precursor cells. However, brown
adipocytes can also appear in WAT and muscle tissue
without carrying the Myf5 signature, for example, after
chronic cold exposure or β-adrenergic stimulation [58].
Both, transdifferentiation of white adipocytes into brown
adipocytes (‘brown in white’ so called ‘brite’ or ‘beige’
adipocytes) and the occurrence of specific precursors
of brown adipocytes in WAT are currently discussed
(Figure 3). In a very recent publication by Wu et al.
[59] it was demonstrated that ‘brite’ adipocytes have ex-
tremely low basal expression of Ucp1, but, like classical
brown adipocytes, they respond to cAMP stimulation
with high Ucp1 expression and respiration rates. Data
from UCP1 expression studies suggest that a lean adult
possesses one brown adipocyte scattered in 100–200
white adipocytes of visceral adipose tissue [60]. In a re-
cent publication by Vegiopoulus et al. [61] cyclooxygen-
ase 2 (COX2) activity and prostaglandines (PGs) have
been implicated as downstream effectors of β-adrenergic
signaling in WAT, which shift progenitor cells towards a
brown adipocyte phenotype. Boström et al. [62] have
shown that PGC-1α stimulated the expression of several
muscle gene products such as the newly identified type I
membrane protein irisin (encoded by the murine gene
Fndc5), which was found in mouse and human plasma
and is secreted after exercise. Overexpession of Fndc5
in mice resulted in 3–4 fold increase of irisin plasma
levels and induced browning of subcutaneous fat and
thermogenesis. Moderately increased irisin expression
in high-fat diet-treated obese and insulin-resistant mice
resulted in reduction of body weight and improvement
of diet-induced insulin resistance. Moreover, ‘brite’ adi-
pocytes have been shown to be preferentially sensitive
to irisin [59].
In another study by Ohno et al. [63] it has been shown
that PPARγ agonists like rosiglitazone induce the brown-
ing of subcutaneous white adipose tissue through
stabilization of the PRDM16 protein. NPs through
NPRA, cGMP, and PKG can activate p38α MAPK to
increase mitochondrial biogenesis and uncouple respir-
ation in human white adipocytes. It has also been
demonstrated that atrial NP and β-AR agonists can act
together in an additive manner to more robustly pro-
mote brown adipocyte features and functions in human
white adipocytes [33]. In this context it is noteworthy
that expression of Pde5 has been described in white
adipocytes [64,65]. Inhibition of PDE5 with sildenafil
triggered the differentiation of white preadipocytes [66].
Therefore, PDE5 blockade in adipose tissue should lead
to increasing intracellular cGMP levels and could also
have an impact on brown adipocyte differentiation and
browning of WAT. This hypothesis is further
Figure 3 Control of ‘brite’ (brown) adipocyte development. The scheme depicts the interplay of white adipocytes, myocytes, and
mesenchymal precursor cells involved in the (trans-) differentiation process of ‘brite’ and/or brown adipocytes. Abbreviations: BMP7, bone
morphogenic protein 7; cAMP, cyclic adenosine monophosphate; CB1, cannabinoid type 1 receptor; C/EBPβ, CCAAT/enhancer binding protein β;
cGMP, cyclic guanosine monophosphate; COX2, cyclooxygenase 2; Fndc5, fibronectin type III domain containing 5; NE, norepinephrin; NPs,
natriuretic peptides; PGs, prostaglandines; PGC1α, PPARγ-coactivator 1α; PRDM16, PR domain containing 16; T3, triiodothyronine; TZDs,
thiazolidinediones; UCP1, uncoupling protein 1.
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vardenafil in human WAT explants resulted in a
marked increase in PPARG and PGC1A expression
paired with an increase in mitochondrial DNA content
[67]. However, data on Pde5 expression in brown adi-
pocytes are still lacking (reviewed in [68]). Blockade of
cannabinoid type 1 receptor (CB1) with rimonabant, a
selective antagonist of the CB1 receptor expressed on
white adipocytes, induces transdifferentiation of differ-
entiated murine white adipocytes towards a brown fat
phenotype [69]. In addition to its function on BAT, T3
has also been implicated in the induction of brown-like
adipocytes in WAT [70] (Figure 3).
Physiological relevance of BAT in adults
The emerging question however is whether BAT in
adults plays an essential physiological role. A retrospect-
ive analysis of studies with PET and PET-CT scans
showed that under normal conditions BAT was only
detected in about 10% of the examined adults [43,48].
However, histological analysis of biopsies revealed an
approximately three times higher abundance [52].
Prospective studies, where young people were exposed
to cold, concluded that 96% of the subjects showed func-
tional BAT [45]. The controversy of these results isprobably related to the inaccuracy of the PET-CT im-
aging technology. In addition, various factors such as
ambient temperature, food intake or intake of FFA and
the use of β-AR antagonists [50,51] can affect FDG up-
take of the cells, which was not taken into account in
any of the studies. The fact that BAT content decreases
with age while usually WAT content increases with age,
suggests, that BAT may play a role in whole-body energy
homeostasis. In most studies, an inverse correlation of
body mass index (BMI) and incidence of BAT and its ac-
tivity were detected. From a bioenergetic perspective
when activated (e.g. by cold exposure) BAT takes up
about as much glucose as the brain, which is beside
muscles, the main glucose consumer of the body. In an
older review from the 1980s Stock and Rothwell [71]
already calculated that “as little as 80–100 g of brown
fat, producing heat at half its maximal capacity, could
account for approximately 20% of a 70 kg man’s daily
energy expenditure. Thus, this almost insignificant mass
of tissue could make all the difference between him
maintaining weight or gainig up to 20 kg per year.” More
recent studies propose more moderate assumptions: In a
PET-CT scan of a subject 63 g of supraclavicular BAT
were detected. The authors concluded that if this deposit
was fully activated over a year, it would burn energy
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pose tissue and thus would contribute substantially to
energy expenditure [46]. Using a new approach by also
measuring nonesterified fatty acid (NEFA) uptake upon
cold exposure it could be shown that all subjects dis-
played substantial glucose and NEFA uptake in BAT
[72]. An increase of 80% total energy expenditure was
observed during 3 hours of cold exposure and it is likely
that a big portion was mediated by BAT thermogenesis.
The authors calculated that mobilization of 28 g of BAT
lipid reserve would be sufficient to account for the extra
energy of roundabout 250 kcal expended. Taken to-
gether, these studies demonstrate that BAT is undoubt-
edly involved in non-shivering thermogenesis in adults.
As main sources of energy for this process BAT con-
sumes intracellular TG and glucose. However, it remains
to be determined whether frequent and chronic cold ex-
posure leads to relevant energy expenditure or if com-
pensatory mechanisms such as increased appetite might
countervail this effect.
Activation of BAT development and activity by drugs
Improvement of the imaging technology is essential to
further identify (scattered) depots of BAT and measure
its impact on energy expenditure for the treatment of
obesity. A new approach has been reported by Chen
et al. [73], which demonstrated the feasibility of measur-
ing BAT volume and function in vivo by using magnetic
resonance imaging in rats. Nevertheless, it is not clear
yet whether human adults have sufficient BAT (or its
precursor cells), which could be activated to have a
significant long lasting effect on energy expenditure.
Despite all uncertainties BAT appears to be a promising
pharmacological target for the treatment of obesity andTable 1 Possible treatments directly targeting WAT and/or BA
Drug Effect
BMP7 (OP-1TM) BAT activation
BMP8B BAT activation
Sildenafil, vardenafil WAT (trans-) differentiation, (BAT activati
Amrinone WAT lipolysis, (WAT transdifferentiation, B
GC-1, KB-141 BAT activation, (WAT transdifferentiation
T3 BAT activation, (WAT transdifferentiation
BRL-26830, L-796568, N-5984 BAT activation, WAT transdifferentiation,
Bile acids (endogenous ligands) BAT activation
ANP, BNP (endogenous ligands) BAT activation, WAT transdifferentiation
Rimonabant WAT transdifferentiation
TZDs, NS-1, balaglitazone, MRL-24,
(Sulfonylureas)
WAT (trans-) differentiation, BAT activatioassociated diseases like type 2 diabetes. Experiments in
rats and mice give cause for hope that in humans the
activation of specific signaling pathways in BAT can in-
crease its development and activity and thus accelerate
energy expenditure (extensively reviewed in [74]). Sev-
eral approaches are possible (see also Table 1 for drug
substances currently under investigation):
 Cold exposure is the physiological way to increase
BAT development and its activity. For example,
increased BAT has been described for outdoor
workers from Northern Europe [75]. However,
various questions remain to be answered. At what
temperatures BAT is fully activated? How long and
often cold exposure needs to be to achieve notable
effects on energy expenditure? Van Marken
Lichtenbelt [45] for instance reported measurable
BAT activity already after mild cold exposure of
16°C for 2 hours and Saito et al. [49] described
substantial FDG uptake into BAT after exposure of
subjects to 19°C for 2 hours. A significant increase
of BAT thermogenesis and energy expenditure has
very recently been described after only 3 hours of
cold exposure to 18°C [72]. Short term exposure to
lower temperatures and chronic cold exposure and
is influence on BAT activity will have to be
determined in future studies.
 Mimicking cold exposure by pharmacological
activation of BAT with sympathomimetics avoids
cold exposure of patients probably resulting in
higher rates of compliance. β3-AR agonists are
currently under development and show good results
on energy expenditure in rodents. However, clinical
trials in humans so far did not provide the expectedT in obesity and type 2 diabetes
Mechanism of action Target organ Class
Developmental regulator BAT Cytokine
Developmental regulator BAT, CNS
on) PDE5 inhibition WAT, (BAT) Enzyme
inhibitor









TGR5 receptor agonist BAT
NPRA agonsit BAT, WAT
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characteristics of the human and the rodent β3-ARs
[76,77]. Selective thyroid hormone mimetics such as
GC-1 and KB-141 with reduced activity on heart
and muscle promote weight loss in rodents [78,79].
Targeting of the bile acid receptor TGR5 expressed
in BAT leads to an increase in energy expenditure
via D2 activation. Currently, various ligands on
TGR5 are under investigation [73]. Substances that
activate the cGMP-signaling pathway (e.g. NPs,
PDE5 inhibitors) are further examples of promising
substances.
 Activating residing brown fat progenitors in skeletal
muscle and WAT is another approach which could
be envisioned. Among others, a cytokine in focus is
BMP7. BMP7 (OP-1TM) is therapeutically used in the
U.S. for the induction of bone growth and
osteoporosis treatment. Recently, it has been shown
that BMP7 regulates the differentiation of precursor
cells into brown adipocytes. Bmp7-transgenic mice
develop more BAT and have increased energy
expenditure and reduced weight gain [57].
Manipulation of COX2-induced PG signaling of
BAT progenitors localized in WAT represents an
alternative strategy for enhancing BAT activity that
could help protecting against energy surplus and
body weight gain [61].
 Transdifferentiation of white adipocytes into ‘brite’
adipocytes: Agonists of the transcription factor
PPARγ, such as the TZDs rosiglitazone or
pioglitazone, increase the expression of brown fat-
specific proteins (e.g. PGC1α and UCP1) both in fat
cell lines and in white adipose tissue from mice
[80,81]. Also a potential to trigger
transdifferentiation of white adipocytes towards a
brown fat phenotype via the stabilization of the
PRDM16 protein has been proposed for TZDs [63].
PPARγ agonists probably increase the metabolic rate
by stimulating BAT activity and increase whole body
BAT content. However, people with type 2 diabetes
treated with pioglitazone at 45 mg/d for 24 weeks
showed no changes in their metabolic rate, gained
weight, and suffered from fluid retention [82]. The
CB1 antagonist rimonabant acts on white adipocytes
and leads to a transdifferentiation towards a brown
fat phenotype in vitro. Patients treated with
rimonabant show weight loss and improved glucose
homeostasis (RIO study [83,84]) what might be
explained by increased thermogenesis, however,
central effects are probably also involved. In 2006
the European Medicines Agency (EMA)
recommended the approval of rimonabant, the first
drug of this class, as an adjunct to diet and exercise
in treating obesity. However, in October 2008, EMArecommended the suspension of rimonabant
because of its psychiatric side effects [85]. The
NPRA has been implicated in the
transdifferentiation process of human white
adipocytes in vitro and in mouse models in vivo.
Targeting NPRs (or subsequent cGMP signaling) is a
promising new approach. Inhibition of PDE5 might
by a strategy to interfere with cGMP signaling,
however, no human data are available so far.
 Also an ex vivo approach seems feasible. Progenitor
cells can be isolated from liposuctions or muscle
biopsies of an obese donor. These cells can be
induced to differentiate in vitro into brown
adipocytes by treatment with BMP7 or
overexpression of PRDM16 or PGC1A.
Differentiated brown adipocytes can be transplanted
back to the donor where they develop into
functional BAT. This approach yielded remarkable
results when tested in mice [56].
 Targeting the CNS e.g. the leptin signaling pathways
in the hypothalamus might produce SNS effects
specific to BAT. In rodents central application of T3
or BMP8B to hypothalamic nuclei resulted in BAT
activation by modulation of hypothalamic regulatory
circuits [41,42].
Conclusions
Direct targeting of adipose tissue is still far from being a
magic bullet for the treatment of obesity and type 2 dia-
betes. However, new options arise by targeting BAT to
increase energy expenditure. Nevertheless, several ques-
tions remain to be answered before targeting of BAT as
therapeutic option becomes possible. It is still not clear
if chronic BAT activation leads to sufficient energy ex-
penditure to achieve the therapeutic goal of weight loss.
Furthermore, it is not known if compensatory mechan-
isms such as increased appetite might countervail
increased energy expenditure. Well-directed cold expos-
ure appears to be the most physiological stimulus to ac-
tivate BAT. Optimum conditions for a targeted cold
exposure of an anticipated “cold-therapy” need to be fur-
ther elucidated. A pharmacological and cell-based ther-
apy approach seems plausible and many druggable
targets could be identified so far. On the other hand,
many safety concerns remain, requiring the need for the
identification of new drug targets and substances in line
with a careful benefit-risk assessment.
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